GRAIL is trading at $71.34 (4.1% up), rebounding from last week’s biotech volatility and Friday’s sector-wide selloff.
- The advance aligns with a broader risk-on tone across major U.S. indices, which are up over 1% following easing Middle East tensions.
- Supportive macro sentiment is providing a lift to the sector despite a lack of fresh company-specific headlines or fundamental catalysts for the stock today.